SA pharmaceutical manufacturer Adcock Ingram has joined an international coalition of generic drugmakers pledging to work together to accelerate access to Covid-19 treatments for low and middle-income countries via the non-profit Medicines Patent Pool (MPP). 

The MPP was launched 10 years ago by the global health initiative Unitaid, funded by a levy on airline tickets. It has previously struck deals with several pharmaceutical companies to share their patents on treatments for HIV, tuberculosis, and hepatitis C with generic manufacturers in low and middle-income countries, including Adcock Ingram, which signed an agreement to make the HIV treatment dolutegravir...

Subscribe now to unlock this article.

Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).

There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.

Cancel anytime.

Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.

Speech Bubbles

Please read our Comment Policy before commenting.